In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S.
Gbyli R, et al. Among authors: prebet t.
Leukemia. 2022 May;36(5):1313-1323. doi: 10.1038/s41375-022-01536-x. Epub 2022 Mar 10.
Leukemia. 2022.
PMID: 35273342
Free PMC article.